Hangzhou Sciwind Biosciences Co.
Latest round
- Series C
Last raised
- Oct 2021
Total raised
- $138M
Investors
- 8
About Hangzhou Sciwind Biosciences Co.
Founded in 2017 and headquartered in Hangzhou, China, Sciwind Biosciences is dedicated to the development of therapies targeting metabolic disorders.Sciwind Biosciences specializes in creating and commercializing biopharmaceuticals, particularly concentrating on therapeutic solutions for metabolic diseases, including non-alcoholic steatohepatitis (NASH). The company's primary offerings are GLP-1 receptor agonists, designed to improve glycemic control for patients with Type 2 diabetes by mimicking GLP-1 hormone activity.Sciwind's revenue model is based on B2B partnerships with healthcare institutions, hospitals, and pharmaceutical distributors. These entities procure GLP-1 therapeutics in bulk to serve their patient populations. The pricing aligns with industry standards for biopharmaceuticals, reflecting the costs of developing their innovative drug offerings., Ltd. The company anticipates significant milestones from their lead programs, including XW003, XW004, and XW014. Sciwind aims to expand its product lineup and is actively exploring new markets, particularly targeting regions where regulatory approvals will allow further penetration.
Who invested in Hangzhou Sciwind Biosciences Co.
8 investors across 4 rounds
See all investors in Hangzhou Sciwind Biosciences Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hangzhou Sciwind Biosciences Co.
Who invested in Hangzhou Sciwind Biosciences Co.?
Hangzhou Sciwind Biosciences Co. has 8 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hangzhou Sciwind Biosciences Co. raised?
Hangzhou Sciwind Biosciences Co. has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Hangzhou Sciwind Biosciences Co. last raise money?
Hangzhou Sciwind Biosciences Co.'s most recent round on record is a Series C, in Oct 2021.
What does Hangzhou Sciwind Biosciences Co. do?
Founded in 2017 and headquartered in Hangzhou, China, Sciwind Biosciences is dedicated to the development of therapies targeting metabolic disorders.
Where is Hangzhou Sciwind Biosciences Co. headquartered?
Hangzhou Sciwind Biosciences Co. is headquartered in Hangzhou, China.
Which VCs invest in companies like Hangzhou Sciwind Biosciences Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Hangzhou Sciwind Biosciences Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like Hangzhou Sciwind Biosciences Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.